The Policy: Medicare's BALANCE Model In July 2026, Medicare launches the GLP-1 Bridge, an interim six-month pilot covering semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) for beneficiaries with a BMI of 30 or higher, or BMI of 27 or higher with an obesity-related comorbidity (diabetes, cardiovascular disease, hypertension)
Medical Oversight : Is there a real board-certified clinician reviewing your medical history and prescribing the medication
So, what can YOU do to improve your glutathione
There was no significant difference between these two treatment strategies overall (HR 0.88, 95% CI 0.68 to 1.14, p = 0.35)
In real-world practice, uncertainty in diabetes care is more common than many clinicians expect
Cruelty-Free